GlucoTrackGCTK
GCTK
About: GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
Employees: 6
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
133% more funds holding
Funds holding: 3 [Q2] → 7 (+4) [Q3]
120% more capital invested
Capital invested by funds: $60.2K [Q2] → $133K (+$72.5K) [Q3]
0.46% more ownership
Funds ownership: 0.55% [Q2] → 1.0% (+0.46%) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for GCTK.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks
Neutral
GlobeNewsWire
1 month ago
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a “best efforts” public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share. The combined offering price of each share of common stock together with the accompanying series A and series B common warrants is $1.39, and the combined offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $1.389. The gross proceeds of the public offering were approximately $10 million before deducting placement agent fees and offering expenses.
Neutral
GlobeNewsWire
1 month ago
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024. Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings.
Neutral
GlobeNewsWire
2 months ago
GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference
Neutral
GlobeNewsWire
3 months ago
JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
Neutral
GlobeNewsWire
4 months ago
Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept
Neutral
GlobeNewsWire
4 months ago
GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE
Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that an emerging science industry poster will be presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference to be held August 9-12, 2024 in New Orleans, LA. The Glucotrack poster will present market research data on the acceptance of the Company's Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes.
Neutral
GlobeNewsWire
6 months ago
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS
Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
Neutral
GlobeNewsWire
6 months ago
GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy
Neutral
GlobeNewsWire
6 months ago
GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE
Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference.
Charts implemented using Lightweight Charts™